Bristol Myers Squibb raises 2026 guidance, cites pipeline progress across four programs

Bristol Myers Squibb reported second-quarter 2026 results on July 30, 2026, and used the release to detail several pipeline updates alongside raised financial guidance.

On July 30, the FDA accepted the supplemental Biologics License Application for Reblozyl with concomitant janus kinase inhibitor therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell transfusions.¹ The acceptance was supported by results from the Phase 3 INDEPENDENCE study, and the FDA granted a PDUFA date of March 11, 2027.¹

Earlier, on July 13, the FDA accepted a New Drug Application for mezigdomide paired with carfilzomib and dexamethasone (MeziKd) for relapsed or refractory multiple myeloma, setting a PDUFA date of May 13, 2027.¹ The filing was based on positive results from the Phase 3 SUCCESSOR-2 trial.¹ The company noted that mezigdomide is the second BMS CELMoD program this year to receive a PDUFA date for an RRMM indication, following iberdomide, whose PDUFA date is August 17, 2026.¹

On the Camzyos (mavacamten) front, the FDA on June 1 accepted for priority review a supplemental New Drug Application covering adolescents ages 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy, based on data from the Phase 3 SCOUT-HCM trial.¹

The company also cited external trial data on izalontamab brengitecan (iza-bren), reported with partner SystImmune. Sichuan Biokin Pharmaceutical, SystImmune's parent company, reported positive results from prespecified interim analyses of two Phase 3 studies, in which iza-bren achieved statistically significant and clinically meaningful improvements in overall survival and progression-free survival in heavily pretreated triple-negative breast cancer and esophageal squamous cell carcinoma, according to the release.¹

On guidance, Bristol Myers Squibb raised its full-year non-GAAP revenue outlook from approximately $46.0 billion to $47.5 billion to a new range of approximately $49.0 billion to $50.0 billion.¹ Non-GAAP EPS guidance was increased to a range of $6.75 to $7.00.¹ The company also raised its 2026 worldwide Eliquis revenue growth projection to 20% to 25%, up from a prior range of 10% to 15%.¹